Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has received a consensus recommendation of “Moderate Buy” from the twenty-seven ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $779.4545.

A number of analysts have commented on REGN shares. UBS Group lifted their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Canaccord Genuity Group raised their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Royal Bank Of Canada increased their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Finally, Scotiabank raised their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 7.02% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Activest Wealth Management increased its stake in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares in the last quarter. Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $27,000. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $31,000. Finally, Caitlin John LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $34,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $784.97 on Monday. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $792.77. The business has a 50-day moving average price of $703.50 and a 200 day moving average price of $610.90. The company has a market capitalization of $82.50 billion, a P/E ratio of 18.80, a PEG ratio of 2.26 and a beta of 0.37. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business posted $12.46 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.